Gause A, Roschansky V, Tschiersch A, Smith K, Hasenclever D, Schmits R, Diehl V, Pfreundschuh M
Laboratories of Immunology and Tumor Biology, Medizinische Klinik, University of Cologne, Germany.
Ann Oncol. 1991 Feb;2 Suppl 2:43-7. doi: 10.1007/978-1-4899-7305-4_7.
In order to evaluate the clinical significance of soluble interleukin-2 receptor (sIL-2R) levels in the serum of patients with Hodgkin's disease (HD), we tested the pretreatment sera of 82 patients. The HD patients had significantly higher sIL-2R levels than normal controls (4787 U/ml versus 290 U/ml; P less than 0.001). In patients presenting with B-symptoms, the median sIL-2R levels were significantly higher than in patients without B-symptoms (7978 versus 2128 U/ml; P less than 0.01). Patients in stage IVB had the highest sIL-2R levels (10,450 U/ml). Of 77 patients evaluable for response, all patients with sIL-2R levels less than 1000 U/ml achieved complete remission and no relapses occurred in this group after a median of 20 months. The fact that sIL-2R levels dropped after therapy, even in patients who suffered from progressive disease, suggests that Hodgkin and Reed-Sternberg cells are only a minor source of sIL-2R in HD. Therefore sIL-2R levels are of limited value as a marker of disease activity. However, pretreatment sIL-2R levels less than 1000 U/ml define a subgroup of adult HD patients with an excellent prognosis, and this fact might be helpful for the design of more custom-tailored therapy programs.
为了评估霍奇金病（HD）患者血清中可溶性白细胞介素-2受体（sIL-2R）水平的临床意义，我们检测了82例患者的治疗前血清。HD患者的sIL-2R水平显著高于正常对照组（4787 U/ml对290 U/ml；P<0.001）。有B症状的患者，其sIL-2R水平中位数显著高于无B症状的患者（7978对2128 U/ml；P<0.01）。IVB期患者的sIL-2R水平最高（10450 U/ml）。在77例可评估反应的患者中，所有sIL-2R水平低于1000 U/ml的患者均实现完全缓解，该组患者在中位20个月后无复发。即使是患有进展性疾病的患者，治疗后sIL-2R水平也会下降，这表明霍奇金和里德-斯腾伯格细胞只是HD中sIL-2R的次要来源。因此，sIL-2R水平作为疾病活动标志物的价值有限。然而，治疗前sIL-2R水平低于1000 U/ml可确定一组预后极佳的成年HD患者亚组，这一事实可能有助于设计更具针对性的治疗方案。
